NATURAL CAPSULES LTD.

Natural Capsules Ltd has announced the closure of its trading window for dealing in the company's equity shares. This closure is effective from October 01, 2026, and will continue until 48 hours after the declaration of the financial results for the quarter ended September 30, 2026. The decision aligns with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The date of the board meeting to approve these financial results will be communicated separately.

Natural Capsules Ltd has completed the dispatch of a Corrigendum to its Extra-Ordinary General Meeting (EGM) Notice, originally scheduled for September 9, 2026. This amendment incorporates changes to the issue price and quantity of Equity Shares and Convertible Warrants to be issued on a preferential basis. The revised terms include up to 1,12,500 Equity Shares at ₹178 per share and up to 4,50,000 Convertible Warrants at ₹178 per warrant. These changes follow a Valuation Report dated August 31, 2026, and queries from BSE & NSE. The Corrigendum is available on the company's website.

Natural Capsules Ltd's Board of Directors approved revised terms for a preferential issue, including up to 1,12,500 equity shares and 4,50,000 convertible warrants. The issue price for both shares and warrants is set at ₹178 per unit. The issuance is directed towards the promoter/promoter group, with Mr. Sunil L Mundra identified as the sole investor. The company also approved a corrigendum notice for an Extra Ordinary General Meeting scheduled for September 9, 2026. The board meeting was convened on short notice due to the late receipt of a valuation report.

Natural Capsules Ltd has scheduled a Board of Directors meeting for September 2, 2026, to consider and approve a preferential issue of equity shares/convertible securities. The meeting will review an updated valuation report from a registered valuer, address queries from BSE & NSE, and potentially revise the issue/allotment price and quantity. The board will also approve a corrigendum to the General Meeting notice. The meeting is convened at shorter notice due to urgent regulatory timelines. The trading window remains closed until 48 hours after the board meeting's outcome.

Natural Capsules Ltd has announced that the cut-off date, also known as the record date, for its upcoming Extraordinary General Meeting (EGM) has been fixed for September 2nd, 2026. The EGM itself is scheduled to take place on September 9th, 2026. This announcement serves to inform shareholders of the specific date by which they must be registered to be eligible to attend and vote at the EGM. The company has formally communicated this record date to relevant authorities and stakeholders for their records.

Natural Capsules Ltd has announced an Extraordinary General Meeting (EGM) to be held on September 9, 2026, to approve the issuance of 1,25,000 equity shares at ₹160 per share, totaling ₹2 crore. This preferential allotment is to Mr. Sunil Laxminarayan Mundra, a promoter. The relevant date for determining the issue price is August 10, 2026. The meeting will be conducted via video conference, and the notice has been filed with the stock exchanges and uploaded on the company's website.

Natural Capsules Ltd announced that Mr. Pramod Kasat has resigned as an Independent Director from its material unlisted subsidiary, Natural Biogenex Private Limited. The resignation is effective from August 17, 2026. The company cited 'Professional Commitments' as the reason for his departure. This change pertains to the governance structure of the subsidiary and is disclosed as per SEBI regulations.

Natural Capsules Ltd announced the approval of its unaudited consolidated and standalone financial results for the quarter ended June 30, 2026. The Board of Directors also approved a preferential issue of up to 1,25,000 equity shares and 5,00,000 convertible warrants to promoter group entities at an issue price of ₹160 per share/warrant. The company is also proceeding with the draft notice for an Extra Ordinary General Meeting to seek member approval for these issuances. M/S Deepak Sadhu has been appointed as the Scrutinizer for the e-voting process.

Natural Capsules Limited announced its unaudited financial results for the quarter ended June 30, 2026. The company reported revenue of ₹48.71 Cr and a Profit After Tax (PAT) of ₹5.74 Cr. The Executive Director highlighted a strong operational quarter for the capsules business, with sustained demand and improved realisations. Challenges included a temporary disruption from a new ERP system and a mixed picture for the API business due to geopolitical uncertainty and currency headwinds. The company is optimizing HPMC capacity by converting lines to gelatine and progressing on API contract manufacturing and regulatory milestones. Demand trends remain firm for Q2FY27.

Natural Capsules Ltd's material unlisted subsidiary, Natural Biogenex Private Limited, has appointed Mr. K. H. Honneshaiah as its new Chief Operating Officer. Mr. Honneshaiah brings 36 years of extensive experience in operations and manufacturing leadership within the regulated pharmaceutical sector, including API, polymers, and peptides. His background encompasses scaling pharma plants, building greenfield capacity, and driving profitable growth, indicating a strategic move to strengthen operational capabilities within the subsidiary.